Pharmacokinetic and pharmacodynamic implications in inhalable antimicrobial therapy

Advanced Drug Delivery Reviews
Jatinder Kaur MukkerH Derendorf

Abstract

Inhaled antimicrobials provide a promising alternative to the systemically delivered drugs for the treatment of acute and chronic lung infections. The delivery of antimicrobials via inhalation route decreases the systemic exposure while increasing the local concentration in the lungs, enabling the use of antimicrobials with severe systemic side effects. The inhalation route of administration has several challenges in pharmacokinetic (PK) and pharmacodynamic (PD) assessments. This review discusses various issues that need to be considered during study, data analysis, and interpretation of PK and PD of inhaled antimicrobials. Advancements overcoming the challenges are also discussed.

References

Dec 17, 1992·The New England Journal of Medicine·P A NixonC F Doershuk
Dec 1, 1991·Antimicrobial Agents and Chemotherapy·A GudmundssonS Gudmundsson
Nov 1, 1989·The American Review of Respiratory Disease·P J AndersonJ Heyder
Mar 1, 1986·Journal of Clinical Pharmacology·J GoldfarbA V Mascia
Jun 1, 1987·Antimicrobial Agents and Chemotherapy·R L DavisA L Smith
Dec 1, 1987·The American Review of Respiratory Disease·J S IlowiteG C Smaldone
Mar 1, 1994·Respiratory Medicine·S MukhopadhyayF Carswell
Nov 25, 1993·The New England Journal of Medicine·B L Ashby, D H Stern
Jul 1, 1993·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·C KönigJ Blaser
Jan 1, 1993·Annual Review of Medicine·N Høiby
Jul 1, 1997·Pediatric Pulmonology·D G Bosworth, D W Nielson
Dec 31, 1997·American Journal of Respiratory and Critical Care Medicine·P DiotG C Smaldone
Mar 11, 2000·Critical Reviews in Therapeutic Drug Carrier Systems·A Hoffman, D Stepensky
Dec 6, 2000·The European Respiratory Journal·G DöringD J Touw
Dec 9, 2000·American Journal of Respiratory and Critical Care Medicine·B FaurouxA Harf
Dec 19, 2000·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·L V SacksS Hurwitz
Mar 27, 2001·The Journal of Antimicrobial Chemotherapy·J W Mouton, N Punt
Jan 10, 2002·Journal of Pharmaceutical Sciences·Bernd Meibohm, Hartmut Derendorf
Mar 20, 2002·Pharmacotherapy·Robert J Kuhn
May 23, 2002·Antimicrobial Agents and Chemotherapy·D Andes, W A Craig
Oct 25, 2002·Journal of Aerosol Medicine : the Official Journal of the International Society for Aerosols in Medicine·Hak-Kim ChanIven Young
Nov 18, 2003·British Journal of Clinical Pharmacology·N R Labiris, M B Dolovich
Jan 15, 2004·American Journal of Respiratory Medicine : Drugs, Devices, and Other Interventions·Mario CazzolaSerafino A Marsico
Jan 27, 2004·Antimicrobial Agents and Chemotherapy·Markus MuellerHartmut Derendorf
Jul 27, 2004·Journal of Chemical Information and Computer Sciences·Christel A S BergströmPer Artursson
Oct 7, 2004·Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society·Gerd DöringUNKNOWN Consensus Study Group
Dec 4, 2004·Nature Medicine·Stuart B Levy, Bonnie Marshall
Jan 25, 2005·International Journal of Antimicrobial Agents·Ping LiuHartmut Derendorf
Mar 12, 2005·The Journal of Antimicrobial Chemotherapy·Rajesh Pandey, G K Khuller
Apr 22, 2005·British Journal of Clinical Pharmacology·A I Al-AmoudH Chrystyn
Jan 7, 2006·The Journal of Antimicrobial Chemotherapy·F RatjenH Grasemann
Mar 7, 2006·Infection·A Dalhoff
Jun 30, 2006·Respiratory Medicine·Ranjan SuriAndrew Bush
Dec 5, 2006·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Paul G AmbroseGeorge L Drusano

❮ Previous
Next ❯

Citations

Aug 21, 2015·Expert Opinion on Drug Delivery·Tiffanie Daisy Sugianto, Hak-Kim Chan
Dec 16, 2016·Drug Development and Industrial Pharmacy·Stefano GiovagnoliMaurizio Ricci
Jul 4, 2018·AAPS PharmSciTech·Lilian Henriques do AmaralLucio Mendes Cabral
Jan 9, 2021·Expert Opinion on Drug Delivery·Maria Gabriella MateraMario Cazzola

❮ Previous
Next ❯

Related Concepts

Related Feeds

Aminoglycosides

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Bacterial Pneumonia

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.

Bacterial Pneumonia (ASM)

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.

Aminoglycosides (ASM)

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

© 2021 Meta ULC. All rights reserved